Showing 2191-2200 of 4063 results for "".
- Nicox Signs Agreement for NCX 4251 in China with Ocumension Therapeutics for Up to €12 Millionhttps://modernod.com/news/nicox-signs-agreement-for-ncx-4251-in-china-with-ocumension-therapeutics-for-up-to-e12-million/2476710/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 4251—currently in a phase 2 trial in the United States in patients with acute exacerbations of blepharitis—for a territo
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis
- Nidek Launches Upgraded AngioScan OCT-Angiography Softwarehttps://modernod.com/news/nidek-launches-upgraded-angioscan-oct-angiography-software/2476265/Nidek has announced the launch of new AngioScan upgraded OCT-Angiography software that enables visualization of retinal and choroidal microvasculature and blood flow using the RS-3000 Advance 2 OCT device. The
- Diabetes Eye Exam Frequency in US Is ‘Alarmingly Low’https://modernod.com/news/diabetes-eye-exam-frequency-in-us-is-alarmingly-low/2476288/The frequency of eye exams among insured patients with type 1 and type 2 diabetes in the United States is “alarmingly low,” new research indicates, as reported in Medscape. Findings from an analysis of nationwide IBM Wa
- Common Glaucoma Visual Test Lacks Consideration for Central Vision Losshttps://modernod.com/news/common-glaucoma-visual-test-lacks-consideration-for-central-vision-loss/2476195/A common visual field test used to assess severity of glaucoma—the 24-2 visual field (VF) test—may be underestimating the severity of vision loss in many patients, according to a recent study, as reported by
- Imprimis Pharmaceuticals Changes Name to Harrow Healthhttps://modernod.com/news/imprimis-pharmaceuticals-changes-name-to-harrow-health/2476233/Imprimis Pharmaceuticals announced it has formally changed its name to Harrow Health and began trading as “HROW” on the NASDAQ Capital Markets on January 2, 2019. “Our new name reflects our business model of c
- EyePrint Prosthetics Announces Clinical Outcomes Achieved With EyePrintPROhttps://modernod.com/news/eyeprint-prosthetics-announces-clinical-outcomes-achieved-with-eyeprintpro/2480203/EyePrint Prosthetics, a company dedicated to restoring vision to patients who have complex corneal irregularities, announced the clinical outcomes that have been achieved since the EyePrintPRO lens was FDA-cleared 2 y
- Opthea Discontinues Wet AMD Trials After Another Failed Phase 3 Trialhttps://modernod.com/news/opthea-discontinues-wet-amd-trials-after-another-failed-phase-3-trial/2482721/Just a week after Opthea announced that its combination drug candidate—2 mg sozinibercept combined with 2 mg aflibercept—did not meet its primary endpoint in the COAST phase 3 trial, the company announced similar results with its phase 3 ShORe (Study of OPT-302 in
- Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weekshttps://modernod.com/news/novartis-announces-positive-results-from-phase-3-trials-of-beovu-in-dme-including-dosing-intervals-up-to-16-weeks/2479452/Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evalu
- Roche Receives FDA Emergency Use Authorization for New COVID-19 Antibodies Testhttps://modernod.com/news/roche-receives-fda-emergency-use-authorization-for-new-covid-10-antibodies-test/2478610/Roche announced that its Elecsys Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the FDA. The semi-quantitative serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus. The new test tar